Senzime AB

SEZI · Nasdaq Stockholm · Healthcare

2.66SEK −2.9%last day

Price as of 2 October 2026

The price over the past year, with dividends: −57.8%

Performance

1 month

−19.4%

1 year

−57.8%

3 years, per year

−30.0%

5 years, per year

−33.6%

Largest fall, 3 years

−82.2%

Below the peak now

−89.8%

Volatility, 1 year

54.5%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.5

Dividend yield

0.0%

Return on equity

−42.6%

Net margin

−109.3%

Market value

42 m USD

Quality, value and trend

Where Senzime stands against every Nordic stock today. 100 is best.

Quality76

Profitability and a sound balance sheet over time. Better than 76% of Nordic stocks.

Value23

The price measured against earnings, assets and cash flow. Better than 23% of Nordic stocks.

Trend5

The price development over the past year. Better than 5% of Nordic stocks.

Combined20

Quality, value and trend together. Better than 20% of Nordic stocks.

About Senzime

Senzime AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 59 employees.

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis